# Drug-Drug Interaction Study of ABP-671 in Gout Patients

> **NCT07367971** · PHASE1 · RECRUITING · sponsor: **Atom Therapeutics Co., Ltd** · enrollment: 20 (estimated)

## Conditions studied

- Gout Chronic
- Gout
- DDI (Drug-Drug Interaction)

## Interventions

- **DRUG:** ABP-671 plus allopurinol

## Key facts

- **NCT ID:** NCT07367971
- **Lead sponsor:** Atom Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-23
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07367971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07367971, "Drug-Drug Interaction Study of ABP-671 in Gout Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07367971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*